Almost 2 years after we hosted our first Data Integrity in GCP Webinar, many things have changed with regards to regulatory expectations for the design and conduct of clinical trials while others remain as before. The latest revision to ICH E6 (R3) has highlighted the importance of following risk-based approaches to the conduct of the trial and along with the finalized EMA guidance on computerized systems has brought forward the importance of data integrity, data governance and computer system validation.
Join on February 29th to discuss:
- important GCP updates
-requirements for systems, security and validation
-requirements for data integrity and data governance
-regulatory expectations for sponsor responsibilities and vendor oversight
As always, we are going to walk you through recent case studies to explore what can go wrong in clinical trials in case of incompliance and review important lessons to be learnt from past wrong-doings.
Consultant; Subject Matter Expert in GCP, Data Integrity and Quality Management Systems
Dr. Thaleia Papadopoulou is conducting Data Integrity assessments in the Life Science industry within the area of GMP Manufacturing, supports clients with setting up Quality Management Systems and performing Risk Assessments and has been...
Dr. Ulrich Koellisch has been on the forefront of the data integrity initiatives and in his previous eight years. He has supported many organizations in the pharmaceutical and biotech sector executing Data Integrity campaigns. Ulrich has...
James Francum is a seasoned Life Science Compliance expert with 20+ years as GxP-CC CEO. Specializing in FDA, EMA & ANVISA, he's worked in 27+ countries with global Life Sciences Industry players. An MBA holder, he's an active member of related...